Pharmaceuticals

Jiangsu wuzhong

Jiangsu Wuzhong released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 147.84 M, actual EPS CNY -0.0614

Jiangsu Wuzhong released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 784.25 M, actual EPS CNY -0.1246

Jiangsu Wuzhong FY2025 Q3 Earnings Release on October 31, Pre-Market BJT

Jiangsu Wuzhong released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), actual revenue CNY 636.41 M, actual EPS CNY -0.062

Jiangsu Wuzhong released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 319.21 M, actual EPS CNY 0.0358

Jiangsu Wuzhong to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

*ST Suewu expected to lose net profit of 40 to 60 million yuan in the first half of 2025

*ST Sue Wu Investigated for Alleged Disclosure Violations

Chairman of *ST Suzhou Wu Listed for Investigation by CSRC for Information Disclosure Violations

ST Suzhou Wu's Controlling Shareholder Pledged 9.57 Million Shares

Jiangsu Wuzhong Warned for Related Party Fund Occupancy

Jiangsu Wuzhong Reports Revenue Drop and Increased Loss in Q1 2025

Jiangsu Wuzhong released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 317.2 M, actual EPS CNY -0.099

Jiangsu Wuzhong released FY2024 Q4 earnings on April 29 After-Market BJT, actual revenue CNY -48.8 M, actual EPS CNY 0.0362

Jiangsu Wuzhong released FY2024 annual earnings on April 29 After-Market BJT, actual revenue CNY 1.599 B (forecast CNY 2.588 B), actual EPS CNY 0.099 (forecast CNY 0.135)

Jiangsu Wuzhong FY2025 Q1 Earnings Release Scheduled for April 30, Pre-Market BJT

Jiangsu Wuzhong to Release FY2024 Earnings on April 25 After-Market BJT, Forecast Revenue CNY 2.588 B, EPS CNY 0.136

Jiangsu Wuzhong Focuses on AestheFill Partner's Equity Transfer, Agency Rights Valid Until 2032

Jiangsu Wuzhong and its subsidiary prosecuted for fraudulently obtaining export tax rebates

Jiangsu Wuzhong Investigated by CSRC for Information Disclosure Violations

艾力斯

興齊眼藥

恆瑞醫藥

雲南白藥

信立泰

海思科

華潤三九

同仁堂

凱萊英

東阿阿膠

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap